Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData

The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion in 2033, driven by the recent approvals of innovative therapies such as Sarepta Therapeutics and Roche’s Elevidys (delandistrogene moxeparvovec), and Santhera Pharmaceuticals’ Agamree (vamorolone), according to GlobalData, a leading data and […]
Read more

Areteia’s dexpramipexole holds potential to redefine respiratory health, says GlobalData

During the J.P. Morgan 43rd Annual Healthcare Conference in January 2025, Areteia Therapeutics’s CEO, Jorge Bartolome, presented a detailed review of its achievements in 2024 and outlined its 2025 plans to advance innovation in the respiratory space with its flagship candidate dexpramipexole dihydrochloride, the first oral therapy targeting eosinophilic asthma. With multiple ongoing clinical trials […]
Read more

GlobalData tracks 40 years of innovation in FDA review designations

Regulatory authorities, particularly the US FDA, have played a crucial role in accelerating and incentivizing the development of innovative treatments through review designations. Since the first designation in 1984, the FDA has seen a substantial rise in the number of designations granted, reaching 694 in 2020. This surge reflects key pharmaceutical milestones, including the biotech […]
Read more

Intra-Cellular Therapies acquisition will expand Johnson & Johnson’s presence in neurology space, says GlobalData

Johnson & Johnson (J&J) recently announced the acquisition of Intra-Cellular Therapies, a biopharmaceutical company specializing in the development of treatments targeting complex psychiatric and neurological disorders. The deal is the biggest biotech M&A transaction since 2023. As part of the acquisition, J&J will obtain Intra-Cellular’s extensive neurology portfolio, which will allow them to grow its […]
Read more

AstraZeneca’s Fasenra set to revolutionize COPD treatment as Phase III data builds anticipation, says GlobalData

AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 J.P. Morgan Healthcare Conference, is set to transform the chronic obstructive pulmonary disease (COPD) treatment. As the first IL-5-targeting monoclonal antibody in late-stage trials, Fasenra targets eosinophilic inflammation, potentially reshaping treatment standards and reinforcing AstraZeneca’s leadership in respiratory and […]
Read more

GLP-1R gold rush: Emerging biotechs set to challenge market leaders, says GlobalData

The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in sales, with Novo Nordisk and Eli Lilly dominating the sector. However, emerging biotech companies are poised to disrupt this landscape, with promising pipeline products expected to generate substantial revenue and challenge the market leaders by 2030, says GlobalData, a leading […]
Read more

AI is set to improve R&D productivity and lower the costs, says GlobalData

Artificial intelligence (AI) has the potential to significantly reduce pharmaceutical R&D costs by streamlining drug discovery, optimizing clinical trials, and minimizing costly failures through data-driven predictions and effectiveness assessments. This potential was acknowledged by the pharmaceutical industry professionals in a survey* conducted by GlobalData, a leading data and analytics company. GlobalData’s report, “The State of […]
Read more

Ultra-long acting GLP-1R agonists to become future therapeutic options for obesity, says GlobalData

At present, the obesity market is dominated by once-weekly, subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), and in the case of Eli Lilly’s Zepbound/Mounjaro (tirzepatide), also the gastric inhibitory peptide receptor (GIPR). Although most patients seem to be satisfied with the currently available medicines, a weekly injection can sometimes be a burden […]
Read more
1 … 10 11 12 13 14 … 108